MedPath

Evaluation of calcium gluconate on reduction of abdominal pain caused by lead toxicity

Phase 3
Conditions
ead toxicity in opium addicted patients.
Registration Number
IRCT20171009036661N2
Lead Sponsor
Kerman University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

People over 18 years old
Oral users of opioids with a lead level greater than 20

Exclusion Criteria

1. Mental retardation
Neuropathic diseases such as diabetes
Chronic pain syndromes
High blood pressure and heart disease
Contraindications for calcium gluconate injection, including sensitivity to this group of drugs. Kidney stones. Hypercalcemia. Hypophosphatemia.
pregnant patient
Patient with Asthma
Patients suspected of obstructive bowel obstruction or with acute abdominal symptoms
Other diagnosis other than lead poisoning
Use of psychiatric drugs
Chronic severe
History of Morphine Sensitivity

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ead colic. Timepoint: 15 minutes, 30 minutes and an hour later. Method of measurement: Visual Analogue Scale.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath